| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Jacek Rysz | Q24649538 |
| Maciej Banach | Q11765283 | ||
| Agata Bielecka-Dąbrowa | Q59558199 | ||
| Dimitri P Mikhailidis | Q62561943 | ||
| P2860 | cites work | 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration | Q22306346 |
| Serious adverse events experienced by patients with chronic heart failure taking spironolactone | Q28360281 | ||
| The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators | Q28372091 | ||
| ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology | Q55050673 | ||
| Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE ( | Q57396224 | ||
| Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction | Q57396225 | ||
| More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure | Q57396381 | ||
| Sudden death prevention in patients with advanced ventricular dysfunction | Q33174283 | ||
| Electrophysiological remodeling in hypertrophy and heart failure | Q33758963 | ||
| Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases | Q33815762 | ||
| Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study | Q33925600 | ||
| Drug-induced hyperkalemia: old culprits and new offenders | Q34038717 | ||
| Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction | Q34187441 | ||
| Prospective population studies of incident heart failure without data on baseline left ventricular ejection fraction | Q34196732 | ||
| Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure | Q34381803 | ||
| Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology | Q34389554 | ||
| Aldosterone in congestive heart failure | Q34472458 | ||
| Electrocardiography is unreliable in detecting potentially lethal hyperkalaemia in haemodialysis patients | Q34526587 | ||
| ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology | Q34830023 | ||
| Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system | Q35856246 | ||
| Difficulties in maintaining potassium homeostasis in patients with heart failure. | Q36606235 | ||
| Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism | Q37710864 | ||
| Renin inhibitors in chronic heart failure: the Aliskiren Observation of Heart Failure Treatment study in context. | Q37789010 | ||
| Combined neutral endopeptidase inhibitors | Q37842465 | ||
| Myocardial potassium loss and cell depolarisation in ischaemia and hypoxia | Q40615142 | ||
| Aldosterone and antialdosterone therapy in congestive heart failure | Q40869789 | ||
| Functional compartmentation of glycolytic versus oxidative metabolism in isolated rabbit heart | Q40918273 | ||
| Renal vascular response to angiotensin II inhibition in intensive antihypertensive treatment of essential hypertension | Q41412855 | ||
| Dying from heart failure: lessons from palliative care. Many patients would benefit from palliative care at the end of their lives | Q42758759 | ||
| Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure | Q43210363 | ||
| Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases | Q43593878 | ||
| Importance of heart failure as a cause of death. Changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979-1992. | Q43701529 | ||
| Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines | Q44283416 | ||
| Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study | Q44485270 | ||
| Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone | Q44560722 | ||
| How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? | Q45017405 | ||
| Racial differences in potassium disposal. | Q45028917 | ||
| Hyperkalemia associated with inhibitors of the renin-angiotensin-aldosterone system: balancing risk and benefit | Q46318699 | ||
| Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). | Q46340479 | ||
| Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure | Q46445280 | ||
| Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population | Q46458003 | ||
| Clinical factors associated with hyperkalemia in patients with congestive heart failure. | Q46492458 | ||
| The combined effects of hypoxia, high K+, and acidosis on the intracellular sodium activity and resting potential in guinea pig papillary muscle | Q46513540 | ||
| Racial differences in potassium response to spironolactone in heart failure | Q46598462 | ||
| ICD patients with elevated defibrillation threshold: clinical behavior and therapeutic alternatives. | Q46661680 | ||
| The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure | Q46683944 | ||
| Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism | Q46724380 | ||
| Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil | Q46841477 | ||
| Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program | Q46904673 | ||
| Congestive heart failure in the community: trends in incidence and survival in a 10-year period. | Q50539807 | ||
| Spironolactone Reduced Arrhythmia and Maintained Magnesium Homeostasis in Patients With Congestive Heart Failure | Q54996729 | ||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| P304 | page(s) | 2329-2338 | |
| P577 | publication date | 2011-07-19 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | What is the risk of hyperkalaemia in heart failure? | |
| P478 | volume | 12 |
| Q33701269 | Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes. |
| Q35691396 | Lipids, blood pressure, kidney - what was new in 2011? |
| Q38126374 | Medication management of chronic heart failure in older adults |
| Q30893153 | Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort |
| Q36988862 | Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction |
Search more.